Navigation Links
VG Energy's Lipid Enhancement Technology Independently Confirmed in First Phase of Testing for Potential Commercial Production of Biofuels
Date:6/8/2011

SAN MARINO, Calif., June 8, 2011 /PRNewswire/ -- VG Energy, Inc., a majority-owned subsidiary of Viral Genetics, Inc. (Pinksheets: VRAL), has received independent confirmation from BioProcess Algae, LLC of early laboratory studies that verify an increase in yields of algae oils following treatment with VG Energy's Metabolic Disruption Technology (MDT) additives. These test studies hold promise for the use of VG's proprietary technology in the large-scale commercial production of biofuels as well as high-value oils used in cosmetics, food and nutraceuticals, among other products.

"We are pleased but not surprised by these early results," said Viral Genetics CEO Haig Keledjian. "Seeing these positive results has been the confirmation that was needed to go forward with the next phase of this particular study."

The results represent the completion of the first two steps of a viability study that VG Energy retained BioProcess Algae to conduct, originally announced on March 25, 2011. BioProcess Algae initially performed a Feasibility Assessment Study to establish baseline performance of VG's technology, with algal strains provided by VG and additional strains from BioProcess Algae. Recognizing an increase in Mean Nile Red Fluorescence, with the strongest effects seen after 48 hours, the study verifies bench-level results of VG's lipid enhancement technology. The next step will be a Dosage Response Study followed by testing at industrial-scale studies.

The Dosage Response Study, expected to be completed within a month, will determine the optimal dosage for the highest lipid outcome in the plant strains selected, according to Dr. M. Karen Newell Rogers, VG Energy's head of scientific research. "It is important that we are thorough in our studies, dosage and selection in order to continuously move the bar to get the highest yields possible," noted Dr. Newell Rogers.

"Although we've seen these results now internally multiple times, it was impor
'/>"/>

SOURCE VG Energy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio
2. Atherotech Taps Canyons Medical Center Director, Lipidologist as Chief Medical Officer
3. Merck/Schering-Ploughs Zetia and Vytorin Have Lost Substantial Patient Share in Second- and Third-Line Therapy Since Last Years Analysis of Dyslipidemia
4. Atherotechs Advanced Lipid Profile Featured in Lipoprotein and Epidemiology Research at ACC 2010
5. ACCORD Lipid Study Brings new Hope to People With Type 2 Diabetes and Atherogenic Dyslipidemia Says International Academic Foundation
6. Atherotech Emphasizes Predictive Value of VAP(R) Cholesterol Test at National Lipid Association Meeting
7. Expanded Lipoprotein Testing, VAPĀ® Cholesterol Test Discussed at National Lipid Association Summer Clinical Lipid Update
8. Liquid crystal droplets discovered to be exquisitely sensitive to an important bacterial lipid
9. Varian to Showcase RapidArc(TM) Radiotherapy Technology Enhancements at ASTRO 2008
10. Frost & Sullivan Recognizes Martek Biosciences for Unique and Customer-Focused Strategies With Customer Value Enhancement Award
11. HOGGAN Ergo Announces Highly Anticipated Enhancements to the ergoFET Handheld Digital Force Gauge, Greatly Impacting the Field of Ergonomic Research and Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... , Sept. 16, 2014  Donald Fresne, President and CEO ... Stephan Vagner , PhD to its Scientific Advisory Committee. ... Toulouse, France , performed research at Embl ... and at Inserm, the French institute of health and medical ... both at the Curie Institute, Orsay, France ...
(Date:9/16/2014)... TN (PRWEB) September 16, 2014 ... new initiatives to position themselves for their ... for labeling and encoding, Pharma Packaging Solutions ... new hardware and software and new procedures. ... current Good Manufacturing Practices (cGMP), Pharma Packaging ...
(Date:9/16/2014)... Denmark , Sept. 16, 2014  Ascendis ... innovative TransCon technology to address significant unmet medical ... ongoing Phase 2 pediatric study to evaluate once-weekly ... deficiency, or GHD.  The full interim results will ... the GRS and IGF Society, being held October ...
(Date:9/16/2014)... 2014 RENU 28, the world's first and ... available for purchase in Australia and New Zealand in mid-August ... September 16th. The tour will make stops in Brisbane on ... the 18th, Sydney on the 20th, and Melbourne on the ... New Zealand and to educate people about the new product ...
Breaking Biology Technology:New Appointment to the Scientific Advisory Committee at Egenix, Inc. 2Adding Serialization Capabilities and Expanded Capacity, Pharma Packaging Solutions Is Preparing for 89th Year of Business 2Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Global Wellness Company Hosts ASEA Australia Tour September 16-22 2
... OF INDUSTRY, Calif. and HONG KONG, June 30 EFT BioTech ... has successfully completed its inaugural Taiwan Strait passenger voyage which has ... the Taiwan Sun, and the Qatar Tribune. The article states: ... with China on Sunday, making it the first such cross-strait service ...
... Mass., June 30 Microfluidics, a wholly owned ... MFLU), and Particle Sciences Inc. (PSI) have formed ... the most advanced and reliable nanotechnology and formulation ... Pharmaceutical Ingredients (APIs). , , Particle Sciences ...
... from the Taichung Harbor to Xiamen , China ... , , CITY OF INDUSTRY, Calif. and HONG ... announced today that the Company,s subsidiary, Excalibur International Marine Corporation, completed ... 2009. The voyage across the Taiwan Strait takes only 4 ...
Cached Biology Technology:Excalibur International Marine (49% Owned by EFT BioTech Holdings) Completes Inaugural Passenger Crossing of Taiwan Strait 2Excalibur International Marine (49% Owned by EFT BioTech Holdings) Completes Inaugural Passenger Crossing of Taiwan Strait 3Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization 2Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization 3EFT BioTech Holdings, Inc.'s Sea Vessel Completes Inaugural Passenger Voyage Across the Taiwan Strait 2EFT BioTech Holdings, Inc.'s Sea Vessel Completes Inaugural Passenger Voyage Across the Taiwan Strait 3
(Date:9/16/2014)... Johns Hopkins neuroscientists have discovered the "molecular brakes" that ... ear cochleas of mice. These "hair cells" translate sound ... brain and are interpreted as sounds. If the arrangement ... , A summary of the research will be published ... 16. , "The proteins Hey1 and Hey2 act as ...
(Date:9/16/2014)... the dinosaurs 66 million years ago decimated the evergreens ... than their deciduous peers, according to a study led ... journal PLOS Biology . , Applying biomechanical ... leaves of angiosperms flowering plants excluding conifers ... of a diverse plant community thriving during a 2.2 ...
(Date:9/16/2014)... Hesperides vessel returned to Spain culminating the around the ... clear picture of how the global ocean works and ... pollutants from the atmosphere is not limited to coastal ... of the planet, and it is already affecting the ... week in CSIC Residence for Researchers in Barcelona, in ...
Breaking Biology News(10 mins):Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 2The Malaspina Expedition confirms that pollution reaches even the most remote areas of the ocean 3
... is on the rise and may be problematic, according ... the December issue of Obstetrics & Gynecology, Erin Tracy, ... and may present potential pitfalls for patients and physicians. ... have no proven clinical validity whatsoever and are quite ...
... for advanced age-related macular degeneration, researchers from Harvard and ... the cure. A research report published in the December ... endostatin to mice significantly reduced or eliminated abnormal blood ... the disease causes blindness. Our study provides ...
... brain injury and using club drugs have in common" ... chemical chain reaction in the brain, leading to cell death, ... series of studies at UF over the past five years ... MDMA, and other forms of methamphetamine lead to the same ...
Cached Biology News:Direct-to-consumer advertising for genetic tests concerns physicians and may mislead patients 2New treatment for age-related macular degeneration within sight 2Club drugs inflict damage similar to traumatic brain injury 2Club drugs inflict damage similar to traumatic brain injury 3
Request Info...
Automated -80° C sample library for microplates and cryotube racks in SBS format; for integration into automated processes....
... Oxidized LDL (Competitive) EIA Principle: ... the monoclonal antibody 4E6. Oxidized LDL in the ... LDL bound to the microtiter well for the ... a washing st Sample Size: 25 ...
... BUF040A is a diluent that is designed for ... which are paired with a mouse monoclonal coating ... rabbit and mouse proteins to prevent non-specific binding ... • This buffer may be used ...
Biology Products: